XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Oct. 10, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 20, 2018
Dec. 20, 2018
Dec. 31, 2021
Revenue   $ 13,071,800 $ 11,619,076      
Net income (loss)   203,347 (2,173,903)      
Accrued interest   1,033,866       $ 1,019,889
DOC Pharma S.A. [Member]            
Prepaid balance   4,368,794       3,263,241
Accounts payable balance   220,518       565,756
Net prepaid balance   4,148,276        
Accounts receivable balance   2,844,572       2,901,300
Payments to purchase products   687,382 589,261      
Revenue   $ 383,688 $ 290,598      
Description of research and development   Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($289,860) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025.        
DOC Pharma S.A. [Member] | Outsourcing Agreement [Member]            
Agreement term 5 years          
Pieces per product 1,000          
Inventroy purchase   $ 517,566        
Grigorios Siokas Three [Member]            
Additional proceeds from debt   356,085        
Outstanding principal balance           1,293,472
Repayment of loans   22,186        
Net income (loss)   23,490        
Grigorios Siokas [Member]            
Outstanding principal balance   452,720       443,720
Interest rate       4.70%    
Maturity date         Mar. 18, 2019  
Borrowing       $ 1,718,400 $ 1,718,400  
Accrued interest   201,835       200,683
Dimitrios Goulielmos [Member]            
Outstanding principal balance   11,315       $ 11,544
Gain incured   9,229        
Grigorios Siokas Four [Member]            
Additional proceeds from debt   $ 100,000